PH12019502425A1 - Crystalline forms of a jak inhibitor compound - Google Patents

Crystalline forms of a jak inhibitor compound

Info

Publication number
PH12019502425A1
PH12019502425A1 PH12019502425A PH12019502425A PH12019502425A1 PH 12019502425 A1 PH12019502425 A1 PH 12019502425A1 PH 12019502425 A PH12019502425 A PH 12019502425A PH 12019502425 A PH12019502425 A PH 12019502425A PH 12019502425 A1 PH12019502425 A1 PH 12019502425A1
Authority
PH
Philippines
Prior art keywords
crystalline forms
inhibitor compound
crystalline
jak inhibitor
hydrates
Prior art date
Application number
PH12019502425A
Other languages
English (en)
Inventor
Marta Dabros
Venkat R Thalladi
Jerry Nzerem
Melanie A Kleinschek
Glenn D Crater
Original Assignee
Theravance Biopharma R And D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R And D Ip Llc filed Critical Theravance Biopharma R And D Ip Llc
Publication of PH12019502425A1 publication Critical patent/PH12019502425A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12019502425A 2017-05-01 2019-10-25 Crystalline forms of a jak inhibitor compound PH12019502425A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492571P 2017-05-01 2017-05-01
PCT/US2018/030144 WO2018204236A1 (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Publications (1)

Publication Number Publication Date
PH12019502425A1 true PH12019502425A1 (en) 2020-06-29

Family

ID=62165729

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502425A PH12019502425A1 (en) 2017-05-01 2019-10-25 Crystalline forms of a jak inhibitor compound

Country Status (13)

Country Link
US (1) US10251874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619208B1 (cg-RX-API-DMAC7.html)
JP (1) JP7096268B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003121A (cg-RX-API-DMAC7.html)
CN (1) CN110603255B (cg-RX-API-DMAC7.html)
AU (1) AU2018261591B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059790A1 (cg-RX-API-DMAC7.html)
MX (1) MX389014B (cg-RX-API-DMAC7.html)
MY (1) MY200348A (cg-RX-API-DMAC7.html)
PH (1) PH12019502425A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909376TA (cg-RX-API-DMAC7.html)
TW (1) TWI808083B (cg-RX-API-DMAC7.html)
WO (1) WO2018204236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
CA3212635A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI710560B (zh) * 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物

Also Published As

Publication number Publication date
TWI808083B (zh) 2023-07-11
KR20200003121A (ko) 2020-01-08
AU2018261591A1 (en) 2019-11-07
EP3619208A1 (en) 2020-03-11
EP3619208B1 (en) 2023-06-07
TW201900643A (zh) 2019-01-01
CN110603255A (zh) 2019-12-20
US20180311223A1 (en) 2018-11-01
RU2019138700A (ru) 2021-06-02
WO2018204236A1 (en) 2018-11-08
CN110603255B (zh) 2023-02-10
JP2020518582A (ja) 2020-06-25
US10251874B2 (en) 2019-04-09
MX2019012945A (es) 2019-12-16
RU2019138700A3 (cg-RX-API-DMAC7.html) 2022-01-26
MY200348A (en) 2023-12-21
MX389014B (es) 2025-03-20
CA3059790A1 (en) 2018-11-08
AU2018261591B2 (en) 2021-09-02
EP3619208C0 (en) 2023-06-07
SG11201909376TA (en) 2019-11-28
JP7096268B2 (ja) 2022-07-05

Similar Documents

Publication Publication Date Title
MY200348A (en) Crystalline forms of a jak inhibitor compound
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
HK1209105A1 (en) Vegfr3 inhibitors
MX369473B (es) Derivado de indolona sustituido por pirrol, método de preparación del mismo, composición que comprende el mismo y uso del mismo.
HK1209104A1 (en) Vegfr3 inhibitors